<li>astemizole<p>metronidazole will increase the level or effect of astemizole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.<span><br><br></span>metronidazole increases levels of astemizole by decreasing metabolism. Contraindicated. Risk of QT interval prolongation.</p></li><li>axitinib<p>metronidazole increases levels of axitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If unable to avoid coadministration with moderate CYP3A4 inhibitors, monitor closely and reduce dose if necessary .</p></li><li>bcg vaccine live<p>metronidazole decreases effects of bcg vaccine live by pharmacodynamic antagonism. Contraindicated. Wait until Abx Tx complete to administer live bacterial vaccine.</p></li><li>bosutinib<p>metronidazole increases levels of bosutinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>cholera vaccine<p>metronidazole, cholera vaccine. pharmacodynamic antagonism. Avoid or Use Alternate Drug. Avoid coadministration of cholera vaccine with systemic antibiotics since these agents may be active against the vaccine strain. Do not administer cholera vaccine to patients who have received oral or parenteral antibiotics within 14 days prior to vaccination.</p></li><li>cisapride<p>metronidazole will increase the level or effect of cisapride by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.<span><br><br></span>metronidazole increases levels of cisapride by decreasing metabolism. Contraindicated. Risk of QT interval prolongation.</p></li><li>cobimetinib<p>metronidazole will increase the level or effect of cobimetinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If concurrent short term (14 days or less) use of moderate CYP3A inhibitors is unavoidable for patients who are taking cobimetinib 60 mg, reduce the cobimetinib dose to 20 mg. After discontinuation of a moderate CYP3A inhibitor, resume cobimetinib 60 mg. Use an alternative to a moderate CYP3A inhibitor in patients who are taking a reduced dose of cobimetinib (40 or 20 mg daily).</p></li><li>dihydroergotamine<p>metronidazole will increase the level or effect of dihydroergotamine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>dihydroergotamine intranasal<p>metronidazole will increase the level or effect of dihydroergotamine intranasal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>disulfiram<p>disulfiram increases toxicity of metronidazole by decreasing metabolism. Contraindicated. Enhanced CNS &amp; cardiac toxicity.</p></li><li>dronedarone<p>metronidazole will increase the level or effect of dronedarone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>eliglustat<p>metronidazole increases levels of eliglustat by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Moderate CYP3A4 inhibitors are not recommended with eliglustat poor or intermediate metabolizers; reduce eliglustat dose from 84 mg BID to 84 mg once daily in extensive metabolizers .</p></li><li>ergotamine<p>metronidazole will increase the level or effect of ergotamine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>erythromycin base<p>metronidazole will increase the level or effect of erythromycin base by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>erythromycin ethylsuccinate<p>metronidazole will increase the level or effect of erythromycin ethylsuccinate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>erythromycin lactobionate<p>metronidazole will increase the level or effect of erythromycin lactobionate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>erythromycin stearate<p>metronidazole will increase the level or effect of erythromycin stearate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>everolimus<p>metronidazole will increase the level or effect of everolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>fentanyl<p>metronidazole will increase the level or effect of fentanyl by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration of CYP3A4  inhibitors with fentanyl is necessary, monitor patients for respiratory depression and sedation at frequent intervals and consider fentanyl dose adjustments until stable drug effects are achieved.</p></li><li>fentanyl intranasal<p>metronidazole will increase the level or effect of fentanyl intranasal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration of CYP3A4  inhibitors with fentanyl is necessary, monitor patients for respiratory depression and sedation at frequent intervals and consider fentanyl dose adjustments until stable drug effects are achieved.</p></li><li>fentanyl iontophoretic transdermal system<p>metronidazole will increase the level or effect of fentanyl iontophoretic transdermal system by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration of CYP3A4  inhibitors with fentanyl is necessary, monitor patients for respiratory depression and sedation at frequent intervals and consider fentanyl dose adjustments until stable drug effects are achieved.</p></li><li>fentanyl transdermal<p>metronidazole will increase the level or effect of fentanyl transdermal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration of CYP3A4  inhibitors with fentanyl is necessary, monitor patients for respiratory depression and sedation at frequent intervals and consider fentanyl dose adjustments until stable drug effects are achieved.</p></li><li>fentanyl transmucosal<p>metronidazole will increase the level or effect of fentanyl transmucosal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration of CYP3A4  inhibitors with fentanyl is necessary, monitor patients for respiratory depression and sedation at frequent intervals and consider fentanyl dose adjustments until stable drug effects are achieved.</p></li><li>ivabradine<p>metronidazole will increase the level or effect of ivabradine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of ivabradine with moderate CYP3A4 inhibitors.</p></li><li>lovastatin<p>metronidazole will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>naloxegol<p>metronidazole will increase the level or effect of naloxegol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministation of naloxegol with moderate CYP3A4 inhibitors is unavoidable, reduce naloxegol dose to 12.5 mg qDay</p></li><li>olaparib<p>metronidazole will increase the level or effect of olaparib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration with moderate CYP3A inhibitors cannot be avoided, reduce olaparib dose to 200 mg PO BID</p></li><li>pimozide<p>metronidazole increases levels of pimozide by decreasing metabolism. Contraindicated. Risk of QT interval prolongation.</p></li><li>propylene glycol<p>metronidazole, propylene glycol. Mechanism: decreasing metabolism. Contraindicated. Disulfiram like reaction.</p></li><li>ranolazine<p>metronidazole will increase the level or effect of ranolazine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>sertindole<p>metronidazole will increase the level or effect of sertindole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>silodosin<p>metronidazole will increase the level or effect of silodosin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>simvastatin<p>metronidazole will increase the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>sirolimus<p>metronidazole will increase the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>terfenadine<p>metronidazole will increase the level or effect of terfenadine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.<span><br><br></span>metronidazole increases levels of terfenadine by decreasing metabolism. Contraindicated. Risk of QT interval prolongation.</p></li><li>tolvaptan<p>metronidazole will increase the level or effect of tolvaptan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>typhoid vaccine live<p>metronidazole decreases effects of typhoid vaccine live by pharmacodynamic antagonism. Contraindicated. Wait until Abx Tx complete to administer live bacterial vaccine.</p></li><li>venetoclax<p>metronidazole will increase the level or effect of venetoclax by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If a moderate CYP3A inhibitor must be used, reduce the venetoclax dose by at least 50%. Monitor more closely for signs of venetoclax toxicities.</p></li><li>warfarin<p>metronidazole increases levels of warfarin by decreasing metabolism. Avoid or Use Alternate Drug.</p></li>